HCPCS code J9022: Atezolizumab injection, per 10 mg2026 Medicare rate & RVUs

Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.

What J9022 covers

Atezolizumab is an intravenous monoclonal antibody that blocks PD-L1, an immune checkpoint protein. Oncology clinicians use it in treatment regimens for several cancers, including lung, bladder, and liver cancers. The drug is administered by infusion in settings such as a physician’s office or hospital outpatient department. Atezolizumab may be given alone or with other cancer drugs; the regimen and administration service are distinct from the drug itself.

J9022 represents 10 mg of atezolizumab, so 1,200 mg corresponds to 120 units. CMS excludes the code from the physician fee schedule (status E). When Medicare covers the drug, payment is under another method; CMS classifies it as a Part B drug generally priced using its quarterly Average Sales Price drug files. Coverage is left to the Medicare contractor’s judgment. Report the drug units separately from any applicable infusion administration service.

This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.

Where J9022 pays more and less

The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.

109 of 109 payment localities

J9022 rates by state

Office rate range in each state. Select a state to see its payment localities.

How the J9022 rate is calculated

Each of J9022’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.

Payment rules and modifiers for J9022

J9022 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.

J9022 compared with similar codes

How to choose

J9024Atezolizumab injectionPer 5 mg

J9024 describes atezolizumab with hyaluronidase for subcutaneous administration; J9022 is the atezolizumab injection code in 10 mg units.

J9023Avelumab injectionPer 10 mg

J9023 identifies avelumab, a different immune checkpoint drug. Use the code for the drug actually administered, not the shared drug class.

J9035BevacizumabPer 10 mg

J9035 identifies bevacizumab, a separate drug that may accompany atezolizumab in a cancer regimen. It does not represent atezolizumab.

Codes related to J9022

Related codes aren’t interchangeable: bill the code that matches the service performed.

Where these rates come from

FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.

CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027

Open CMS sourceHow we calculate rates